ReferenceRRK6204

A first-in-human double-blind randomized placebo-controlled Phase 1 study to evaluate the safety tolerability reactogenicity and immunogenicity of JNJ-64300535 a DNA vaccine administered by intramuscular injection and electroporation in subject with chronic Hepatitis B who are virologically suppressed and on stable nucleos(t)ide therapy

Research Summary

Research Overview
PI Name Mutimer - DJ
Speciality
Project Status Open
Proposed End Date 30/06/2021
Study Run through CRF? No
Target number of patients agreed to recruit 2
Recruitment so far 2